20 completed, 7 terminated, 1 unknown, 1 withdrawn. 16 Phase 2, 15 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 9, Terminated 5, Unknown 1, Withdrawn 1 |
| Phase 1 | 15 | Completed 13, Terminated 2 |
| Phase 3 | 1 | Completed 1 |
Follow Cilengitide: new trials by email Literature Review of Cilengitide trials Research Report on Cilengitide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) Cilengitide, Bevacizumab, Questionnaire - Glioblastoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-06-01 | 2018-01-19 | |
| Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents Cilengitide, Temozolomide - Gliomas | Phase 2 | Terminated | Martin-Luther-Universität Halle-Wittenberg | 28 | 2012-01-01 | 2015-07-21 |
| Pharmacokinetics in Subjects With Renal Impairment cilengitide 2000mg, cilengitide 1000mg, cilengitide > 1000mg and up to 2000mg - Renal Impairment | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 32 | 2012-01-01 | 2014-02-04 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery Cilengitide, Laboratory Biomarker Analysis, Paclitaxel - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2010-12-01 | 2016-03-15 |
| Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma Cilengitide dose escalation, Cilengitide, Concomitant radiotherapy - Diffuse Intrinsic Pontine Glioma | Phase 1 | Completed | Centre Oscar Lambret | 32 | 2010-09-06 | 2026-03-16 |
| Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 | Completed | National Cancer Institute (NCI) | 47 | 2010-03-01 | 2015-04-15 |
| Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer cilengitide, radiochemotherapy - Locally Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | Institut Claudius Regaud | 14 | 2010-03-01 | 2026-04-14 |
| Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme Cilengitide, Clinical Observation, Laboratory Biomarker Analysis - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 41 | 2009-12-01 | 2015-04-28 |
| Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene Cilengitide - Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4 | Phase 2 | Unknown | Northern Sydney and Central Coast Area Health Service | 48 | 2009-11-01 | 2011-07-26 |
| Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma Cetuximab, Cilengitide EMD 121974 - Glioblastoma | Phase 2 | Terminated | Bart Neyns | 12 | 2009-09-01 | 2012-03-22 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide - Glioblastoma | Phase 2 | Completed | EMD Serono | 265 | 2009-03-01 | 2017-01-30 |
| Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) Cilengitide, Cetuximab, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 232 | 2009-02-01 | 2017-01-13 |
| Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer cilengitide, pharmacological study, radiation therapy - Brain and Central Nervous System Tumors, Lung Cancer | Phase 1 | Completed | Universitätsmedizin Mannheim | 19 | 2008-12-01 | 2024-05-10 |
| Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Cilengitide 2000 mg once weekly, Cilengitide 2000 mg twice weekly, Cetuximab - Squamous Cell Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 184 | 2008-10-01 | 2014-04-30 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Cilengitide, Temozolomide, Radiotherapy - Glioblastoma | Phase 3 | Completed | EMD Serono | 545 | 2008-09-01 | 2014-11-04 |
| Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy cilengitide, laboratory biomarker analysis, pharmacological study - Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2008-06-01 | 2018-08-01 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme cilengitide, temozolomide, radiation therapy - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 112 | 2005-04-01 | 2016-02-25 |
| Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme cilengitide, therapeutic conventional surgery, pharmacological study - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 30 | 2005-01-01 | 2017-06-14 |
| Cilengitide in Treating Patients With Metastatic Prostate Cancer cilengitide, laboratory biomarker analysis - Recurrent Prostate Cancer, Stage IV Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 106 | 2005-01-01 | 2013-02-28 |
| Cilengitide in Treating Patients With Prostate Cancer cilengitide - Recurrent Prostate Cancer, Stage I Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2005-01-01 | 2016-04-28 |
Showing 20 of 29. Sign in to see all of them.
Glioblastoma (12) · Brain Neoplasms (6) · Gliosarcoma (5) · Astrocytoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Lymphoma, Follicular (3) · Oligodendroglioma (3) · Recurrence (3) · Burkitt Lymphoma (2) · Central Nervous System Neoplasms (2) · Diffuse Intrinsic Pontine Glioma (2) · Glioma (2) · Hodgkin Disease (2) · Immunoblastic Lymphadenopathy (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2)
National Cancer Institute (NCI) (14) · EMD Serono (3) · Merck KGaA, Darmstadt, Germany (3) · Bart Neyns (1) · Centre Oscar Lambret (1) · Indiana University (1) · Institut Claudius Regaud (1) · M.D. Anderson Cancer Center (1) · Martin-Luther-Universität Halle-Wittenberg (1) · New Approaches to Brain Tumor Therapy Consortium (1) · Northern Sydney and Central Coast Area Health Service (1) · Universitätsmedizin Mannheim (1)
United States (19) · Germany (7) · France (4) · Belgium (3) · Italy (2) · Poland (2) · Spain (2) · Australia (1) · Austria (1) · Canada (1) · Czechia (1) · Hungary (1) · Ireland (1) · Switzerland (1)
Andriy Markivskyy, MD (2) · Maha Hussain (2) · Tobey MacDonald (2) · Andreas Becker, MD MSc (1) · Barbara J. Klencke, MD (1) · Bart Neyns (1) · Christian Manegold, MD (1) · Christof M. Kramm, MD (1) · Elizabeth Gerstner (1) · Jan Vermorken, MD, PhD (1) · Julian Molina (1) · Kevin Kim (1) · Louis B. Nabors, MD (1)
PMID 36346112, PMID 17470857, PMID 18981465, PMID 21049281, PMID 22517399, PMID 24567516, PMID 25163906, PMID 25939894, PMID 29221762
2009 (3), N01CM62202 (2), 2008 (1), N01CM62206 (1), P30CA014599 (1), P30CA015083 (1), U01CA062399 (1), U01CA062475 (1), U01CA069852 (1), U01CA069912 (1), U01CA081457 (1), U01CA099176 (1), U01CA137443 (1), U10CA098543 (1)